5 news items
Merck Ends Keytruda Combo Melanoma Study Due to Futility
ANIP
LGND
MRK
14 May 24
monotherapy and combination studies. Merck is also working on different strategies to drive the long-term growth of Keytruda. These include innovative
Ligand Reports First Quarter 2024 Financial Results
AMGN
CASI
JAZZ
7 May 24
Long
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
AGEN
LGND
7 May 24
cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
ALDX
LGND
MRK
27 Feb 24
Long
Ligand Pharmaceuticals's Earnings: A Preview
LGND
26 Feb 24
, shares are up 3.87%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release
- Prev
- 1
- Next